Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity.

Authors: Kim SH, et al.
Published in Sci Rep. 2020
Non-alcoholic fatty liver disease (NAFLD) is considered a hepatic manifestation of metabolic syndrome and is associated with cardiovascular outcomes. The authors investigated whether NAFLD was associated with coronary artery calcification (CAC) in participants without a previous history of cardiovascular disease and whether this association differed...
Read MoreAssociation between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity.

Microbiome as a therapeutic target in alcohol-related liver disease.

Authors: Sarin SK, Pande A, Schnabl B.
Published in J Hepatol. 2019
Alcohol-related liver disease is associated with significant changes in gut microbial composition. Treatment approaches on the gut microbiota, such as diet, probiotics, antibiotics and faecal microbial transplantation can restore intestinal homeostasis and improve alcohol-related liver disease (1). Dysbiosis of the intestinal microbiota...
Read MoreMicrobiome as a therapeutic target in alcohol-related liver disease.

The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study.

Authors: Lee JM, Park YM, Yun JS, et al.
Published in PLoS One. 2020
The authors investigated the association between nonalcoholic fatty liver disease (NAFLD) and gastrointestinal tract cancer in the general population. Retrospective data on individuals aged ≥20 years who received healthcare checkups from January 1, 2009 to December 31, 2009 were analyzed using the National Health Insurance Database in Korea. NAFLD was defined...
Read MoreThe association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study.

The role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician

Prof. Kenneth Cusi
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Read MoreThe role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician

auses of mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol related Fatty Liver Disease (AFLD).

Authors: Johnston MP, Patel J, Byrne CD.
Published in Current Pharmaceutical Design. 2020
Non-alcoholic fatty liver disease (NAFLD) and alcohol related fatty liver disease (AFLD) both represent a spectrum of liver disease severity from hepatic steatosis to fibrosis and cirrhosis. It is often not possible to distinguish between NAFLD and AFLD on examination of liver histology, consequently, differentiation between NAFLD and AFLD is heavily reliant...
Read Moreauses of mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol related Fatty Liver Disease (AFLD).

Fibroblast growth factor signalling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma

Authors: Ocker M.
Published in World J Gastroenterol. 2020
Fibroblast growth factors and their receptors play an important role in maintaining metabolic homeostasis also in the liver and disorders in signalling what have been identified to contribute to those pathophysiologic conditions leading to hepatic lipid accumulation and chronic inflammation. While specific and well tolerated inhibitors...
Read MoreFibroblast growth factor signalling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma

Prognostic value of non-alcoholic fatty liver disease in the elderly patients

Authors: Tallarico V, Recinella G, Magalotti D, et al
Published in Aging Clin Exp Res 2020
There is very little information about NAFLD in the geriatric patients. V. Tallarico et al. (Division of Internal Medicine, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy) investigated the independent prognostic value of NAFLD on overall mortality in the elderly. 804 subjects were followed up for mortality for a median...
Read MorePrognostic value of non-alcoholic fatty liver disease in the elderly patients

Complications, morbidity and mortality of nonalcoholic fatty liver disease.

Authors: Mantovani A, Scorletti E, Mosca A, et al.
Published in Metabolism. 2020<
Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized public health problem, affecting up to a quarter of the world’s adult population. The burden of NAFLD is influenced by the epidemics of obesity and type 2 diabetes mellitus (T2DM) and the prevalence of these conditions is not expected to decrease in the forthcoming decades...
Read MoreComplications, morbidity and mortality of nonalcoholic fatty liver disease.

Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease

Authors: Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE
Published in Aliment Pharmacol Ther. 2020 Feb
Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of cardiovascular disease. It is not well understood, however, which individuals with NAFLD are at highest risk for cardiovascular disease. This study aimed to determine the factors associated with incident cardiovascular events in a prospective cohort of individuals...
Read MoreAdvanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease

Flaxseed oil in the context of a weight loss program ameliorates fatty liver grade in patients with non-alcoholic fatty liver disease: a randomized double-blind controlled trial

Authors: Rezaei S, Sasani MR, Akhlaghi M, et al.
Published in Br J Nutr 2020
Long-chain omega-3 fatty acids have shown to regulate lipid metabolism and reduce fat accumulation in the liver. Masoumeh Akhlaghi et al. (Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran) investigated the effect of flaxseed oil, as a rich source...
Read MoreFlaxseed oil in the context of a weight loss program ameliorates fatty liver grade in patients with non-alcoholic fatty liver disease: a randomized double-blind controlled trial

Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study.

Authors: VanWagner LB et al.
Published in J Am Heart Assoc. 2020;9(4):e014279.
Non-alcoholic fatty liver disease (NAFLD) is associated with high cardiovascular morbidity/mortality, including heart failure. Abnormalities in left ventricular (LV) structure/function are associated with heart failure risk. Participants from the population-based CARDIA (Coronary Artery Risk Development in Young Adults) study...
Read MoreLongitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study.

Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way

Authors: Abenavoli L, Boccuto L, Federico A, et al.
Published in Int J Environ Res Public Health. 2019;16(17):E3011.
Nowadays, the cornerstone in the clinical management of NAFLD includes two easy and pivotal concepts that are: dietary modification associated with improvement of physical activity. In the era of evidence-based medicine, for L. Abenavoli et al. (Department of Health Sciences, University “Magna Graecia”, Catanzaro, Italy)...
Read MoreDiet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES